ライフサイエンスコーパス: contraceptive

1 ral, Depo-Provera injection, patch, and ring contraceptives).

2 get, e.g. for diabetes, glaucoma, and a male contraceptive.

3 lability of F5-peptide as a prospective male contraceptive.

4 germ cell loss, and thus is a promising male contraceptive.

5 ivered the MZC combination microbicide and a contraceptive.

6 nst the known benefits of a highly effective contraceptive.

7 t for a nonhormonal, readily reversible male contraceptive.

8 logical effects to injectable progestin-only contraceptives.

9 sis on development of long-acting reversible contraceptives.

10 mother, age at hysterectomy, or use of oral contraceptives.

11 y the typical effectiveness of all available contraceptives.

12 ons that commonly occur in women on hormonal contraceptives.

13 ntraception; most counseling focused on oral contraceptives.

14 obesity and in the development of novel male contraceptives.

15 development of new fertility treatments and contraceptives.

16 be leveraged to increase WTP for injectable contraceptives.

17 , and halved with use of estrogen-containing contraceptives.

18 47% were provided to new users of injectable contraceptives.

19 while increasing rural access to injectable contraceptives.

20 che and after excluding those using hormonal contraceptives.

21 e than among women who had not used hormonal contraceptives.

22 tion was found in women who did not use oral contraceptives.

23 t address adherence problems noted with oral contraceptives.

24 ng risk factor for CVT in women who use oral contraceptives.

25 heterogeneity compared with using other oral contraceptives = 0.004) was associated with particularly

26 formin vs placebo or estrogen-progestin oral contraceptives, (3) insulin-sensitizing agents, and (4)

27 epo-Provera, patch, or ring; 22.4% used oral contraceptives; 40.8% used condoms; 11.8% used withdrawa

28 rt, 152 women used injectable progestin-only contraceptives, 43 used other forms of contraception, an

29 %), contraceptive injections (57%), and oral contraceptives (51%).

30 1.5%] vs 3220 [52.5%]), more often used oral contraceptives (97 [72.9%] vs 758 [23.5%] of women), and

31 examine changes in the number of claims for contraceptives according to method for 2 years before an

32 Oral contraceptives (adjusted relative risk [RR], 2.02 [95% c

33 d the wide-spread clinical use of EE as oral contraceptive adjuvant, the impact of these estrogenic e

34 gy for the development of novel and specific contraceptive agents that block oocyte maturation and/or

35 nd halved with use of an estrogen-containing contraceptive (AHR = 0.5; 95% CI, .3-.8).

36 Guidelines for contraceptive and ART combinations should balance the fa

37 gnancy rates among women receiving different contraceptive and ART combinations.

38 evidence linking such communication to youth contraceptive and condom use has not been empirically sy

39 rone (P4), is extensively used by women as a contraceptive and in hormone replacement therapy.

40 ccessfully develop an approved male hormonal contraceptive and to identify long-term side-effects.

41 Previous studies of oral contraceptives and breast cancer indicate that recent us

42 for the rational development of non-hormonal contraceptives and fertility treatments for humans and o

43 eduction, 35.5%) for long-acting, reversible contraceptives and from 6832 to 4708 (relative reduction

44 Estradiol-based contraceptives and hormonal replacement therapy predispo

45 Progestins are components of human contraceptives and hormone replacement pharmaceuticals a

46 stins are widely used as a component in both contraceptives and in hormone replacement therapy (HRT),

47 hose impact is strongly enhanced by hormonal contraceptives and mediated by sex hormone-binding globu

48 Oral contraceptives and pregnancies had a significantly highe

49 etween premenopausal volunteers free of oral contraceptives and those who used oral contraceptives (P

50 Females receiving hormonal contraceptives and those with an abnormal vaginal pH had

51 (CBRHAs) were trained to provide injectable contraceptives and were provided with a loan of 25 injec

52 C (intrauterine device or implant), (2) oral contraceptives, and (3) Depo-Provera, patch, or ring.

53 than among women who had never used hormonal contraceptives, and this risk increased with longer dura

54 progestin-only therapy, or combined hormonal contraceptives are effective for controlling HMB.

55 Hormonal contraceptives are the most widely used contraceptive me

56 Participants categorized each contraceptive as "most effective, >99% effective," "medi

57 Among women using injectable contraceptives at baseline, we observed rates of contrac

58 Intake of oral contraceptives (beta, 0.150; 95% CI, 0.0649 to 0.236) an

59 way for community distribution of injectable contraceptives but sustaining such efforts remains chall

60 Short-acting contraception methods (eg, oral contraceptives) can be used as a temporary bridge to pro

61 The Contraceptive CHOICE Project was a large prospective coh

62 Women cited multiple influences on their contraceptive choices, including friends, family, physic

63 f HIV infection in women using combined oral contraceptives (COCs) or the injectable progestins depot

64 Current treatments include oral contraceptives combined with nonsteroidal anti-inflammat

65 r and (ii) pristimerin and lupeol can act as contraceptive compounds by averting sperm hyperactivatio

66 elines state that use of estrogen-containing contraceptives confers an "unacceptable health risk" dur

67 ptives, there was a reduction in the rate of contraceptive continuation and an increase in the rate o

68 raceptives at baseline, we observed rates of contraceptive continuation through the program and of ch

69 tin secretion and the complexities of making contraceptive decisions in the context of a serious ment

70 The injectable hormonal contraceptive depo-medroxyprogesterone acetate (DMPA) ha

71 ereas 16% had never heard of an intrauterine contraceptive device (IUD).

72 ondition in adolescents and is a recommended contraceptive device in sexually active adolescent women

73 oung women in the United States use hormonal contraceptives during their reproductive years.

74 eptive effectiveness knowledge and change in contraceptive effectiveness knowledge after viewing the

75 Preintervention contraceptive effectiveness knowledge and change in cont

76 erum LNG was at levels associated with local contraceptive effects.

77 or severe oligozoospermia, commensurate with contraceptive efficacy.

78 l triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy, or a

79 nerally stable, the slight trends in TTP and contraceptive failure being in opposite directions, like

80 apine-based ART, these women still had lower contraceptive failure rates than did those receiving all

81 z-based ART had a three-times higher risk of contraceptive failure than did those using nevirapine-ba

82 ble as a male cohort effect for both TTP and contraceptive failure.

83 st half of the study period for both TTP and contraceptive failure.

84 on time to pregnancy (TTP) and proportion of contraceptive failures.

85 received efavirenz-based ART, accompanied by contraceptive failures.

86 higher among the women who had used hormonal contraceptives for 5 years or more than among women who

87 th CD receiving the combination type of oral contraceptives for at least 1 year, 1 extra surgery is r

88 ed use and did not examine contemporary oral contraceptive formulations.

89 d were provided with a loan of 25 injectable contraceptives from a drug revolving fund, created with

90 in 8.7% (n = 70) of women who used hormonal contraceptives greater than or equal to 1 year compared

91 raceptive method which can be used to inform contraceptive guidelines, models, and future studies.

92 (age range, 15-19 years) using combined oral contraceptives had an RR of a first use of an antidepres

93 mpared with nonusers, users of combined oral contraceptives had an RR of first use of an antidepressa

94 e acetate (DMPA) or non-specified injectable contraceptives had heterogeneous methods and mixed resul

95 The use of injectable progestin-only contraceptives has been associated with increased risk o

96 Hormonal contraceptives (HCs) inhibit estrogen production; yet, t

97 How are hormonal contraceptives (HCs) related to marital well-being?

98 a cessation of menstruation, use of another contraceptive, history of miscarriage or abortion for th

99 d pack-years), alcohol, family history, oral contraceptive, hormones, physical activity, and diet.

100 Contraceptive implants and intrauterine devices (IUDs) a

101 Thirty-four percent had never heard of contraceptive implants, whereas 16% had never heard of a

102 bout efavirenz reducing the effectiveness of contraceptive implants.

103 clinical studies and found to act as an oral contraceptive in combination with a progestin, without i

104 Women using no long-term contraceptive in the luteal phase of the menstrual cycle

105 and adolescent girls become users of modern contraceptives in 69 of the world's poorest countries by

106 ed 501 couples who were discontinuing use of contraceptives in order to become pregnant for the Longi

107 a model for increasing access to injectable contraceptives in rural settings by using community-base

108 use of hormone replacement therapy, and oral contraceptives in women.

109 rectly identify the typical effectiveness of contraceptives increased for almost all methods (subderm

110 the RR estimates for users of combined oral contraceptives increased to 1.7 (95% CI, 1.66-1.71).

111 women spent less than 1 minute reviewing the contraceptive information sheet (mean [SD], 31 [27] seco

112 A contraceptive information sheet can significantly improv

113 Prior to viewing the contraceptive information sheet, more than half of women

114 women who returned for a subsequent on-time contraceptive injection decreased from 56.9% among those

115 the typical effectiveness of condoms (75%), contraceptive injections (57%), and oral contraceptives

116 In a 7-y experiment we used contraceptive injections to manipulate the distribution

117 uricatta) for three breeding attempts, using contraceptive injections.

118 Recent use of oral contraceptives involving high-dose estrogen (OR, 2.7; 95

119 suggest that recent use of contemporary oral contraceptives is associated with an increased breast ca

120 tradiol (EE2), a synthetic oestrogen in oral contraceptives, is one of many pharmaceuticals found in

121 on sheet can significantly improve patients' contraceptive knowledge and may be a useful addition to

122 n women receiving long-acting progestin-only contraceptives (LAPCs) are unknown.

123 o promote the use of long-acting, reversible contraceptive (LARC) methods to reduce unintended pregna

124 e patients' access to long-acting reversible contraceptives (LARCs) on pregnancy rates.

125 ne devices (IUDs) are long-acting reversible contraceptives (LARCs) that are known to be highly effec

126 mpared with 19.2% (n = 57) of women who used contraceptives less than 1 year (incidence rate per 100

127 rone or a synthetic analog found in hormonal contraceptives, levonorgestrel, impacts sequential influ

128 ignificantly in the presence of the hormonal contraceptive medroxyprogesterone acetate (MPA) and prog

129 ns should balance the failure rates for each contraceptive method and ART regimen combination against

130 The primary exposure was a combination of contraceptive method and efavirenz-based or nevirapine-b

131 Contraceptive method at last sexual intercourse was asse

132 onal contraceptives are the most widely used contraceptive method in sub-Saharan Africa, the most HIV

133 We support efforts to increase the contraceptive method mix for all women, regardless of HI

134 ata to provide summary estimates by hormonal contraceptive method which can be used to inform contrac

135 However, roughly 20% of couples using a contraceptive method worldwide, and up to 80% in some co

136 ice, the basic principle of the T-based male contraceptive method, that a specific T dose could maint

137 oral contraceptive or another less effective contraceptive method.

138 ed withdrawal or other method; 15.7% used no contraceptive method; and 1.9% were not sure.

139 We assessed rates of contraceptive-method provision, method continuation thro

140 en who switched from hormonal to nonhormonal contraceptive methods (and vice versa) across different

141 compared with users of moderately effective contraceptive methods (ie, oral, Depo-Provera injection,

142 Use of modern contraceptive methods also increased, and the overall pr

143 r between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevi

144 responsibility, but available male-directed contraceptive methods are either not easily reversible (

145 knowledge of the typical effectiveness of 8 contraceptive methods before and after reviewing an educ

146 e number of claims for short-acting hormonal contraceptive methods during this period.

147 ure rates than did those receiving all other contraceptive methods except for intrauterine devices an

148 LARC devices constitute first-line contraceptive methods for adolescents.

149 Long-acting reversible contraceptive methods include intrauterine devices (IUDs

150 Access to a wide range of highly effective contraceptive methods is needed for women, particularly

151 uent follow-up than in this study, and other contraceptive methods should also be assessed.

152 is teratogenic but had less understanding of contraceptive methods that effectively prevent pregnancy

153 Women using other contraceptive methods, except for intrauterine devices a

154 tive age defined by their marital status and contraceptive need and use, and the sizes of these subgr

155 can occur in a subset of women who use oral contraceptives (OCs) with uncertain metabolic consequenc

156 e of exogenous hormones, in the form of oral contraceptives (OCs), has been linked consistently to ri

157 o be exposed, such as men in studies on oral contraceptives (OCs).

158 story.IMPORTANCE The impact of hormone-based contraceptives on the outcome of infectious diseases out

159 one application, such as the use of hormonal contraceptives, on HIV acquisition risk.

160 is necessary to normalize offering LARC as a contraceptive option and improve its uptake among adoles

161 A shorter acting contraceptive option is the transdermal patch.

162 icians carefully should evaluate and monitor contraceptive options among women with established CD.

163 g the need for additional safe and effective contraceptive options for women at high HIV risk.

164 populations can also be offered appropriate contraceptive options inclusive of LARC.

165 tation can be safely offered a wide range of contraceptive options to suit their individualized needs

166 There is a large range of contraceptive options, varying in drug formulation, rout

167 el about LARC even before suggesting an oral contraceptive or another less effective contraceptive me

168 ted with PMS was not modified by use of oral contraceptives or antidepressants but was attenuated amo

169 Safer sex behavior, including use of contraceptives or condoms.

170 rectal cancer is reduced among users of oral contraceptives or menopausal hormone therapy, but associ

171 ch can be managed with short courses of oral contraceptives or nonsteroidal anti-inflammatory drugs.

172 Respondents who had ever used injectable contraceptives or who were interested in using them were

173 according to whether they were using modern contraceptives, or had unmet need for modern methods (ie

174 cation revealed that, in women who used oral contraceptives, overweight and obesity were associated w

175 ells) compared with women using no long-term contraceptive (p=0.0241).

176 oral contraceptives and those who used oral contraceptives (P = .28-0.82) and between premenopausal

177 8 (relative reduction, 31.1%) for injectable contraceptives (P<0.001 for both comparisons).

178 n on the relative effectiveness of available contraceptives, participants expressed surprise that thi

179 et, smoking, alcohol intake, and use of oral contraceptives (per 1-unit increase in BMI, mean differe

180 international debate occurred when the oral contraceptive pill ("the Pill" or "OCP") was approved.

181 zard ratio [aHR], 0.6; 95% CI, .4-1.2), oral contraceptive pill (aHR, 0.8; 95% CI, .3-2.1), nor impla

182 We included 21 nonoral contraceptive pill (non-OCP) users who self-collected va

183 pletely resolved after cessation of the oral contraceptive pill (OCP) and associated adenoma regressi

184 the associations between sex hormones, oral contraceptive pill (OCP) use, systemic inflammation and

185 tionally, the combined oestrogen-progestagen contraceptive pill might decrease lamotrigine concentrat

186 dings could not be explained by differential contraceptive pill use.

187 menopausal females were not matched for oral contraceptive pill use.

188 ith sex and 66 molecules varied between oral contraceptive pill users, postmenopausal females, and fe

189 intrauterine device (LNG-IUD; n = 27), oral contraceptive pills (n = 32), or no hormonal contracepti

190 Oral contraceptive pills (OCPs) have been associated with imp

191 an increased HIV risk in ten studies of oral contraceptive pills (pooled HR 1.00, 0.86-1.16) or five

192 aemia, lipid profile, parity and use of oral contraceptive pills in females, smoking and alcohol inta

193 of the studies that assessed the use of oral contraceptive pills showed no significant association wi

194 tion", "injectables", "progestin", and "oral contraceptive pills".

195 s, and seven also reported findings for oral contraceptive pills.

196 Behavioral and contraceptive practices may modify the effectiveness of

197 coming pregnant and only 1 had a long-acting contraceptive prescribed.

198 ruct estimates and projections of the modern contraceptive prevalence rate (mCPR), unmet need for, an

199 ontinue providing women safe and easy to use contraceptive products.

200 Gestodene is a human contraceptive progestin and a potent activator of fish a

201 In this study, the ability of the contraceptive progestin levonorgestrel to bind chemicall

202 their intended use, progesterone (P4)-based contraceptives promote anti-inflammatory immune response

203 icates that female sex hormones and hormonal contraceptives regulate susceptibility to human immunode

204 ancer than women who had never used hormonal contraceptives (relative risk, 1.21; 95% CI, 1.11 to 1.3

205 , including history of rape, sexual assault, contraceptive sabotage, and coerced decision-making, was

206 ts and compensate workers with proceeds from contraceptive sales.

207 d data to measure the intervention effect on contraceptive selection, and used survival analysis to a

208 ning preferences and create more sustainable contraceptive service provision with greater impact.

209 eed to increase resources, improve access to contraceptive services and supplies, and provide high-qu

210 ng the number of pregnancies by provision of contraceptive services as part of a Reproductive Health

211 ly struggles with funding, cost recovery for contraceptive services may offer a means of improved fin

212 HIV risk, maternal mortality, and access to contraceptive services.

213 Goal 5, which calls for universal access to contraceptive services.

214 d-gender cohorts and females taking hormonal contraceptives should be considered as a separate sub-co

215 counseled about highly effective reversible contraceptives such as the subdermal implant or intraute

216 making these proteins promising non-hormonal contraceptive targets [1,3].

217 l access to reproductive health services and contraceptive technologies, advancing women's education,

218 ently or recently used contemporary hormonal contraceptives than among women who had never used hormo

219 ss of only a mean (SD) of 3.8 (1.9) of the 8 contraceptives that they were asked about.

220 ly effective (ie, intrauterine or subdermal) contraceptives, the iPLEDGE program increases anxiety ab

221 Among women using injectable contraceptives, the percentage of women who returned for

222 Compared with women who never used hormonal contraceptives, the relative risk among current and rece

223 Six months after starting use of hormonal contraceptives, the RR of antidepressant use peaked at 1

224 Among women who prefer injectable contraceptives, their odds of WTP for injectable contrac

225 For women using injectable contraceptives, there was a reduction in the rate of con

226 omic position, adiposity and use of hormonal contraceptives, there were no associations with any of t

227 ombining antiretrovirals (ARV) and progestin contraceptives to prevent HIV infection and pregnancy.

228 This finding, never addressed in clinical contraceptive trials, is not unexpected in light of the

229 t cancer risk associated with different oral contraceptive types could impact discussions weighing re

230 H-indazole-3-carbohydrazide (adjudin, a male contraceptive under development) causes permanent infert

231 A longer duration of oral contraceptive use (>/=10 years of use compared with neve

232 anic, black women, who reported low rates of contraceptive use (33% versus 17%; P = 0.02) and a STI h

233 ealth" ("Sahatek Sarwetek") on precursors to contraceptive use (e.g., spousal communication, birth sp

234 r trend = 0.02) and increasing years of oral contraceptive use (P for trend = 0.02).

235 Recent oral contraceptive use (within the prior year) was associated

236 ignificantly decreased with duration of oral contraceptive use [per five-year increments OR ESR2-posi

237 The association between hormonal contraceptive use and a first suicide attempt peaked aft

238 Injectable progestin-only contraceptive use and high endogenous progesterone are b

239 In analysis that adjusted for hormonal contraceptive use and marital status, women reporting mu

240 Associations between hormonal contraceptive use and mood disturbances remain understud

241 Data for trends in contraceptive use and need are necessary to guide progra

242 ipants for a longitudinal cohort study about contraceptive use and pregnancy (the Contraceptive Use,

243 sidered potential mediators between hormonal contraceptive use and risk of suicide attempt.

244 thors assessed associations between hormonal contraceptive use and suicide attempt and suicide in a n

245 We therefore aimed to estimate trends in contraceptive use and unmet need in developing countries

246 c diagnoses, antidepressant use, or hormonal contraceptive use before age 15 and who turned 15 during

247 of menorrhagia, which was managed with oral contraceptive use for 20 years; this was stopped in 2013

248 age, sex, race, parental education, and oral contraceptive use found a significant positive relations

249 5% uncertainty interval 46.4-62.1) in modern contraceptive use in 2015 between subregions.

250 t that specific regimens of combined hormone contraceptive use in MRM and migraine with aura may decr

251 Women were asked about hormonal contraceptive use in the context of a current sexual par

252 Detailed oral contraceptive use information was ascertained from elect

253 re the highest percentage increase in modern contraceptive use to achieve 75% demand satisfied with m

254 We find contraceptive use to be a particularly important contrib

255 d associations with age at menarche and oral contraceptive use warrant further investigation.

256 Current hormonal contraceptive use was positively associated with inciden

257 Higher educational level, prior oral contraceptive use, and higher weight at baseline, as wel

258 Conversely, breastfeeding, oral contraceptive use, and late age at first pregnancy were

259 udies with adjustment for smoking, BMI, oral contraceptive use, and parity, compared to studies witho

260 e focus here on patterns of sexual activity, contraceptive use, and post-conception outcomes such as

261 evels and trends in the prevalence of modern contraceptive use, and unmet need and demand for family

262 s, age at menarche, age at first birth, oral contraceptive use, bilateral oophorectomy, estrogen plus

263 ling, with adjustment for age, smoking, oral contraceptive use, body mass index, menopausal status, p

264 Parity, oral contraceptive use, cigarette smoking, age at menarche, a

265 smoking, physical activity, menopause, oral contraceptive use, hormone therapy, and field center.

266 status, age at menopause, BMI, smoking, oral contraceptive use, MHT use, and an interaction term betw

267 and MHT use; the ovarian model included oral contraceptive use, MHT use, and family history or breast

268 itment (advertisements and promotion) in the Contraceptive Use, Pregnancy Intention, and Decisions (C

269 y about contraceptive use and pregnancy (the Contraceptive Use, Pregnancy Intention, and Decisions (C

270 Age at menarche, oral contraceptive use, pregnancy, parity, age at first and l

271 lenge virus-specific antibody, demographics, contraceptive use, season, and body mass index (PBMC: od

272 year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all inva

273 current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL

274 on as a potential adverse effect of hormonal contraceptive use.

275 se associated with injectable progestin-only contraceptive use.

276 exceeded pre-FP2020 expectations for modern contraceptive use.

277 adjusted for propensity scores for hormonal contraceptive use.

278 tion, birth spacing attitudes) and on modern contraceptive use.

279 lling for menstrual cycle phase and hormonal contraceptive use.

280 cancer, ethnicity, smoking status, and oral contraceptive use.

281 d menopause; number of live births; hormonal contraceptive use; and postmenopausal hormone use.

282 ess likely to use condoms compared with oral contraceptive users (adjusted prevalence ratio [aPR], 0.

283 re recent sexual partners compared with oral contraceptive users (aPR, 2.61; 95% CI, 1.75-3.90) and D

284 lf-reported DMPA users (n = 23), nonhormonal contraceptive users (n = 63), and women who practice vag

285 HIV-negative injectable progestin-only contraceptive users had 3.92 times the frequency of cerv

286 At ages 25-34 years, hormonal contraceptive users had lower mean levels of concurrent

287 ntext of a current sexual partnership; thus, contraceptive users were compared with other sexually ac

288 ortal location is specifically found in oral contraceptive users, associated with an inflammatory con

289 arious oral combination (estrogen-progestin) contraceptives varied between 1.0 and 1.6.

290 raceptives, their odds of WTP for injectable contraceptives vary across length of time they have used

291 rk for pay, their odds of WTP for injectable contraceptives vary by whether they agree with their hus

292 Effects did not differ for contraceptive vs condom use or among longitudinal vs cro

293 ong current and recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 pers

294 However, unmet need for modern contraceptives was still very high in 2012, especially i

295 Women using injectable progestin-only contraceptives were at substantially higher risk of acqu

296 ther types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7).

297 onorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over

298 ynthetic progestin increasingly used in oral contraceptives with similar effects to progesterone (P4)

299 e unmet need for family planning with modern contraceptives would be synergistic, and would contribut

300 aining and 96% believed providing injectable contraceptives would improve their services.